Tissue engineering for urinary incontinence applications

Minerva Ginecologica

Volumn 56, Issue 4, 2004, Pages 371-378

  Koh, C J ^a   Atala, A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder augmentation; Bulking agents; Injectable therapy; Regenerative medicine; Tissue engineering; Urinary incontinence

Indexed keywords

ALGINIC ACID; BIOMATERIAL; BULKING AGENT; COLLAGEN; NATURAL PRODUCT; POLYESTER; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER;

ACELLULAR TISSUE MATRIX; BLADDER AUGMENTATION; BLADDER RECONSTRUCTION; CARTILAGE CELL; CELL BASED GENE THERAPY; CELL CULTURE; CLINICAL TRIAL; ENDOSCOPIC THERAPY; EXTRACELLULAR MATRIX; HUMAN; INJECTABLE THERAPY; INJECTION; MEDICINE; MYOBLAST; REGENERATIVE MEDICINE; REVIEW; STEM CELL; TISSUE ENGINEERING; TISSUE REGENERATION; URINE INCONTINENCE;

FEMALE; HUMANS; MALE; REGENERATIVE MEDICINE; TISSUE ENGINEERING; TREATMENT OUTCOME; URINARY BLADDER; URINARY INCONTINENCE;

EID: 4744338367     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA 2004;291:986-95.
2. Brown JS, Nyberg LM, Kusek JW, Burgio KL, Diokno AC, Foldspang A et al. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on Epidemiologic Issues in Urinary Incontinence in Women. Am J Obstet Gynecol 2003;188:77-88.
3. Burgio KL, Matthews KA, Engel BT. Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women. J Urol 1991;146:1255-9.
4. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obst Gynecol 2001;98:398-406.
5. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
6. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: clinical applications. JAMA 2004;291:996-9.
7. Huard J, Yokoyama T, Pruchnic R, Qu Z, Li Y, Lee JY et al. Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther 2002;9:1617-26.
8. Chen F, Yoo JJ, Atala A. Acellular collagen matrix as a possible "off the shelf" biomaterial for urethral repair. Urology 1999;54:407-10.
9. Dahms SE, Piechota HJ, Dahiya R, Lue TF, Tanagho EA. Composition and biomechanical properties of the bladder acellular matrix graft: comparative analysis in rat, pig and human. Br J Urol 1998;82:411-9.
10. Piechota HJ, Dahms SE, Nunes LS, Dahiya R, Lue TF, Tanagho EA. In vitro functional properties of the rat bladder regenerated by the bladder acellular matrix graft. J Urol 1998;159:1717-24.
11. Yoo JJ, Meng J, Oberpenning F, Atala A. Bladder augmentation using allogenic bladder submucosa seeded with cells. Urology 1998;51:221-5.
12. Amiel GE, Atala A. Current and future modalities for functional renal replacement. Urol Clin North Am 1999;26:235-46, xi.
13. Borer JG, Cisek LJ, Atala A, Diamond DA, Retik AB, Peters CA. Pediatric retroperitoneoscopic nephrectomy using 2 mm instrumentation. J Urol 1999;162:1725-9, discussion 1730.
14. Atala A, Freeman MR, Vacanti JP, Shepard J, Retik AB. Implantation in vivo and retrieval of artificial structures consisting of rabbit and human urothelium and human bladder muscle. J Urol 1993;150(2 Pt 2):608-12.
15. Atala A, Guzman L, Retik AB. A novel inert collagen matrix for hypospadias repair. J Urol 1999;162(3 Pt 2):1148-51.
16. Atala A, Kim W, Paige KT, Vacanti CA, Retik AB. Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension. J Urology 1994;152:641-3, discussion 644.
17. Atala A, Lanza RP. Preface. In: Atala A, Lanza RP, editors. Methods of tissue engineering. San Diego: Academic Press; 2001.
18. Atala A, Mooney D. Preface. In: Atala A, editor. Tissue engineering. Boston: Birkhauser Press; 1997.
19. Cilento BG, Freeman MR, Schneck FX, Retik AB, Atala A. Phenotypic and cytogenetic characterization of human bladder urothelia expanded in vitro. J Urol 1994;152(2 Pt 2):665-70.
20. Fauza DO, Fishman SJ, Mehegan K, Atala A. Videofetoscopically assisted fetal tissue engineering: bladder augmentation. J Pediatr Surg 1998;33:7-12.
21. Fauza DO, Fishman SJ, Mehegan K, Atala A. Videofetoscopically assisted fetal tissue engineering: skin replacement. J Pediatr Surg 1998;33:357-61.
22. Godbey WT, Atala A. In vitro systems for tissue engineering. Ann N Y Acad Sci 2002;961:10-26.
23. Kershen RT, Atala A. New advances in injectable therapies for the treatment of incontinence and vesicoureteral reflux. Urol Clin North Am 1999;26:81-94, viii.
24. Machluf M, Atala A. Emerging concepts for tissue and organ transplantation. Graft 1998;1:31.
25. Oberpenning F, Meng J, Yoo JJ, Atala A. De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nat Biotechnol 1999;17:149-55.
26. Park HJ, Yoo JJ, Kershen RT, Moreland R, Atala A. Reconstitution of human corporal smooth muscle and endothelial cells in vivo. J Urol 1999;162:1106-9.
27. Yoo JJ, Atala A. A novel gene delivery system using urothelial tissue engineered neo-organs. J Urol 1997;158(3 Pt 2):1066-70.
28. Yoo JJ, Lee I, Atala A. Cartilage rods as a potential material for penile reconstruction. J Urol 1998;160:1164-8, discussion 1178.
29. Scriven SD, Booth C, Thomas DF, Trejdosiewicz LK, Southgate J. Reconstitution of human urothelium from monolayer cultures. J Urol 1997;158(3 Pt 2):1147-52.
30. Liebert M, Hubbel A, Chung M, Wedemeyer G, Lomax MI, Hegeman A et al. Expression of mal is associated with urothelial differentiation in vitro: identification by differential display reverse-transcriptase polymerase chain reaction. Differentiation 1997;61:177-85.
31. Puthenveettil JA, Burger MS, Reznikoff CA. Replicative senescence in human uroepithelial cells. Adv Exp Med Biol 1999;462:83-91.
32. Freeman MR, Yoo JJ, Raab G, Soker S, Adam RM, Schneck FX et al. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest 1997;99:1028-36.
33. Nguyen HT, Park JM, Peters CA, Adam RM, Orsola A, Atala A et al. Cell-specific activation of the HB-EGF and ErbB1 genes by stretch in primary human bladder cells. In Vitro Cell Dev Biol Anim 1999;35:371-5.
34. Liebert M, Wedemeyer G, Abruzzo LV, Kunkel SL, Hammerberg C, Cooper KD et al. Stimulated urothelial cells produce cytokines and express an activated cell surface antigenic phenotype. Semin Urol 1991;9:124-30.
35. Tobin MS, Freeman MR, Atala A. Maturational response of normal human urothelial cells in culture is dependent on extracellular matrix and serum additives. Surg Forum 1994;45:786.
36. Harriss DR. Smooth muscle cell culture: a new approach to the study of human detrusor physiology and pathophysiology. Br J Urol 1995;75 Suppl 1:18-26.
37. Solomon LZ, Jennings AM, Sharpe P, Cooper AJ, Malone PS. Effects of short-chain fatty acids on primary urothelial cells in culture: implications for intravesical use in enterocystoplasties. J Lab Clin Med 1998;132:279-83.
38. Lobban ED, Smith BA, Hall GD, Harnden P, Roberts P, Selby PJ et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 1998;153:1957-67.
39. Rackley RR, Bandyopadhyay SK, Fazeli-Matin S, Shin MS, Appell R. Immunoregulatory potential of urothelium: characterization of NF-kappaB signal transduction. J Urol 1999;162:1812-6.
40. Kim BS, Mooney DJ. Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol 1998;16:224-30.
41. Bergsma JE, Rozema FR, Bos RR, Boering G, de Bruijn WC, Pennings AJ. In vivo degradation and biocompatibility study of in vitro predegraded as-polymerized polyactide particles. Biomaterials 1995;16:267-74.
42. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
43. Deuel TF. Growth factors. In: Lanza RP, Langer R, Chick WL, editors. Principles of tissue engineering. New York: Academic Press 1997.p.133-49.
44. Pariente JL, Kim BS, Atala A. In vitro biocompatibility assessment of naturally derived and synthetic biomaterials using normal human urothelial cells. J Biomed Mater Res 2001;55:33-9.
45. Pariente JL, Kim BS, Atala A. In vitro biocompatibility evaluation of naturally derived and synthetic biomaterials using normal human bladder smooth muscle cells. J Urol 2002;167:1867-71.
46. Li ST. Biologic biomaterials: tissue-derived biomaterials (collagen). In: Brozino JD, editor. The biomedical engineering handbook. Boca Raton, FL: CRS Press, 1995.p.627-47.
47. Silver FH, Pins G. Cell growth on collagen: a review of tissue engineering using scaffolds containing extracellular matrix. J Long-Term Eff Med Implants 1992;2:67-80.
48. Sams AE, Nixon AJ. Chondrocyte-laden collagen scaffolds for resurfacing extensive articular cartilage defects. Osteoarthritis Cartilage 1995;3:47-59.
49. Smidsrod O, Skjak-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol 1990;8:71-8.
50. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980;210:908-10.
51. Gilding DK. Biodegradable polymers. In: Williams DF, editor. Biocompatibility of clinical implant materials. Boca Raton, FL: CRC Press; 1981.p.209-32.
52. Freed LE, Vunjak-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK et al. Biodegradable polymer scaffolds for tissue engineering. Biotechnology 1994;12:689-93.
53. Mikos AG, Thorsen AJ, Czerwonka LA, Bao Y, Langer R, Winslow DN et al. Preparation and characterization of poly(L-lactic acid) foams. Polymer 1994;35:1068-77.
54. Harris LD, Kim BS, Mooney DJ. Open pore biodegradable matrices formed with gas foaming. J Biomed Mater Res 1998;42:396-402.
55. Peppas NA, Langer R. New challenges in biomaterials. Science 1994;263:1715-20.
56. Atala A, Cima LG, Kim W, Paige KT, Vacanti JP, Retik AB et al. Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. J Urol 1993;150(2 Pt 2):745-7.
57. Retik AB, Mandell J, Bauer SB, Atala A. Meatal based hypospadias repair with the use of a dorsal subcutaneous flap to prevent urethrocutaneous fistula. J Urol 1994;152:1229-31.
58. Bent A, Tutrone R, McLennan M, Lloyd LK, Kennelly MJ, Badlani G. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. Neurourol Urodynam 2001;20:157-65.
59. Diamond DA, Caldamone AA. Endoscopic correction of vesicoureteral reflux in children using autologous chondrocytes: preliminary results. J Urol 1999;162(3 Pt 2):1185-8.
60. Yokoyama T, Chancellor MB, Watanabe T, Ozawa H, Yoshimura N, Groat WC et al. Primary myoblasts injection into the urethra and bladder as a potential treatment of stress urinary incontinence and impaired detrusor contractility: long-term survival without significant cytotoxicity. J Urol 1999;161:307.
61. Chancellor MB, Yokoyama T, Tirney S, Mattes CE, Ozawa H, Yoshimura N et al. Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourol Urodynam 2000;19:279-87.
62. Strasser H, Marksteiner R, Frauscher F, Bartsch G, Hering S, Klauser A. Transurethral ultrasound guided injection of clonally cultured autologous myoblasts and fibroblasts: experimental results. Presented at the Proceedings of the 2003 International Bladder Symposium, March 6-9, 2003, Arlington, VA.
63. Yiou R, LaFleuchuer J, Atala A. The regeneration process of the striated urethral sphincter involves the activation of intrinsic satellite cells. Anat Embryol 2003;2006:429-35.
64. Yiou R, Yoo JJ, Atala A. Restoration of functional motor units in a rat model of sphincter injury by muscle precursor cell autografts. Transplantation 2003;76:1053-60.